MDCX

Insider Trades

Name	Value	Action	Price	Current Price
Velocity Fund Partners, LP10 Percent Owner $579k75k shares SellMay 20, 2025 $7.72 --

News

proactiveinvestors.comMedicus Pharma submits EU clinical trial modification for prostate cancer drug Teverelixproactiveinvestors.comJun 8

globenewswire.comMedicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submissionglobenewswire.comJun 8

proactiveinvestors.comMedicus Pharma advances SkinJect for Gorlin syndrome – ICYMIproactiveinvestors.comJun 6

proactiveinvestors.comSolidion Technology shares surge after company unveils extreme-climate battery technologyproactiveinvestors.comJun 4

Trade MDCX

About Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.

CEO: Raza Bokhari
IPO Date: Nov 15, 2024

Market Data

Open: $0.3362
High: $0.3448
Low: $0.32
Volume: 863.6K
52W High: $3.69
52W Low: $0.25

Valuation

Market Cap: $7.1M
Enterprise Value: $917k

Financials

Free Cash Flow: $-23M
Revenue: $0
Net Income: $-25M
Cash: $8.7M
Debt: $4.0M

Events

EarningsAug 10

EPS est. -0.14